BTIG Maintains Buy on ArriVent BioPharma, Lowers Price Target to $29
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
BTIG analyst Jeet Mukherjee maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $42 to $29.
BTIG analyst Jeet Mukherjee maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $42 to $29.